CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishSummary Objective: To investigate the usefulness of the milk-to-plasma (M=P) ratio for assessing the risks for the breastfed infant associated with the maternal use of SSRIs. Data sources: Medline, Toxnet, Embase, Current Contents, and PsycInfo indexed articles from 1980 to September 2006. Study selection and data extraction: All studies reporting the M=P ratio in mothers taking SSRIs while breastfeeding or studies which such an information could be calculated from data reported in the article. Data synthesis: Higher M=P ratios were rarely associated with a clinically significant impact on the babies during the early phases of breastfeeding. Conclusions: So far no evidence-based information seems to support the hypothesis that SSRIs characterized by a M=P ratio <1.0 should be preferred. Hence, physicians should consider different parameters when attempting to choose the safest SSRI for the breastfeeding woman. These parameters might be represented by the number of well-documented published adverse event reports and the tendency of each SSRI of inducing in the infants serum concentrations that are elevated above 10% of average maternal serum levels. In any case, if the mother wishes to breastfeed her infant while taking a SSRI, the baby should be closely monitored in order to promptly detect any iatrogenic event. Keywords: Breastfeeding; lactation; milk=plasma ratio; safety; SSRIs.
| Titolo: | SSRIs during breastfeeding: spotlight on milk-to-plasma ratio |
| Autori: | |
| Data di pubblicazione: | 2007 |
| Rivista: | |
| Abstract: | Summary Objective: To investigate the usefulness of the milk-to-plasma (M=P) ratio for assessing the risks for the breastfed infant associated with the maternal use of SSRIs. Data sources: Medline, Toxnet, Embase, Current Contents, and PsycInfo indexed articles from 1980 to September 2006. Study selection and data extraction: All studies reporting the M=P ratio in mothers taking SSRIs while breastfeeding or studies which such an information could be calculated from data reported in the article. Data synthesis: Higher M=P ratios were rarely associated with a clinically significant impact on the babies during the early phases of breastfeeding. Conclusions: So far no evidence-based information seems to support the hypothesis that SSRIs characterized by a M=P ratio <1.0 should be preferred. Hence, physicians should consider different parameters when attempting to choose the safest SSRI for the breastfeeding woman. These parameters might be represented by the number of well-documented published adverse event reports and the tendency of each SSRI of inducing in the infants serum concentrations that are elevated above 10% of average maternal serum levels. In any case, if the mother wishes to breastfeed her infant while taking a SSRI, the baby should be closely monitored in order to promptly detect any iatrogenic event. Keywords: Breastfeeding; lactation; milk=plasma ratio; safety; SSRIs. |
| Handle: | http://hdl.handle.net/11566/36654 |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
Copyright © 2021